榮昌生物(09995.HK)曾飆近49%逼近上市高位 與Seagen訂立獨家全球許可協議
榮昌生物-B(09995.HK)與Seagen(SGEN.US)訂立獨家全球許可協議,該股今早曾飆升近49%高見145.5元,暫受制今年2月所創上市高位149.8元,現報119.5元,急漲22%,成交急增至480萬股。
榮昌生物與Seagen訂立獨家全球許可協議,以開發及商業化維迪西妥單抗,公司將收取首付款2億美元及最多24億美元的里程碑付款。Seagen亦將向公司支付根據銷售金額計算特許權使用費。
該產品已於2021年6月9日正式獲得國家藥品監督管理局(NMPA)在中國的附條件上市的批准,用於治療局部晚期或轉移性胃癌,包括胃食管結合部腺癌(GEJ)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.